RT plus Nimotuzumab

Phase 3

SSun Yat-sen University

RT plus Nimotuzumab is one of 49 therapeutic programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Tuoyi

CCoherus Oncology, Inc.

Phase 3

21 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

20 3

Beyfortus

BeiGene

Phase 3

6 4

Taxotere

AAvyxa

Phase 3

15 5

Tuoyi

SSun Yat-sen University

Phase 3

11 6

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 7

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

6 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 10

Induction Phase1

Genmab

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Nasopharyngeal Carcinoma

NCT04456322

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

A Randomized Non-inferiority Trial of Radiotherapy Plus Nimotuzumab or Cisplatin in Patients With Favorable Response to Induction Chemotherapy for Low-risk Locoregionally Advanced-Staged Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT04456322·381 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RT plus Nimotuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for RT plus Nimotuzumab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

RT plus Nimotuzumab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News